| INSTAPRIN-PHARMACEUTICALS-INC |
INSTAPRIN-PHARMACEUTICALS-INC |
90%
|
The purchase price for the Acquired Assets was $ 3,628,325 plus interest thereon, to be paid to the SEC on behalf of Instaprin in satisfaction of the SEC’s judgment against Instaprin and its former CEO |
| IVPR |
Inspire Veterinary Partners, Inc. |
72%
|
tional Debentures upon the mutual agreement of the Company and the holders of Debentures representing at least a majority of the aggregate principal and interest owed under the outstanding Debentures… |
| IVPR |
Inspire Veterinary Partners, Inc. |
72%
|
Reciprocal relationship from IVPR graph: Reciprocal relationship from ASBP graph: Reciprocal relationship from IVPR graph: Reciprocal relationship from ASBP graph: Reciprocal relationship from IVPR g… |
| SDOT |
Sadot Group Inc. |
72%
|
tional Debentures upon the mutual agreement of the Company and the holders of Debentures representing at least a majority of the aggregate principal and interest owed under the outstanding Debentures… |
| SDOT |
Sadot Group Inc. |
72%
|
Reciprocal relationship from SDOT graph: Reciprocal relationship from ASBP graph: Reciprocal relationship from SDOT graph: Reciprocal relationship from ASBP graph: Reciprocal relationship from SDOT g… |
| ARENA-BUSINESS-SOLUTIONS-GLOBAL-SPC-II-LTD |
ARENA-BUSINESS-SOLUTIONS-GLOBAL-SPC-II-LTD |
62%
|
ceived in exchange for such products. The customer order evidenced by invoices issued is considered to be the contract with the customers. At contract inception, an assessment of the products and ser… |
| ASPIRE-BIOPHARMA-INC |
ASPIRE-BIOPHARMA-INC |
62%
|
tional Debentures upon the mutual agreement of the Company and the holders of Debentures representing at least a majority of the aggregate principal and interest owed under the outstanding Debentures… |
| BLACKSTONE-CAPITAL-ADVISORS-INC |
BLACKSTONE-CAPITAL-ADVISORS-INC |
62%
|
tional Debentures upon the mutual agreement of the Company and the holders of Debentures representing at least a majority of the aggregate principal and interest owed under the outstanding Debentures… |
| CLOSING-DATE-ASPIRE-BIOPHARMA-INC |
CLOSING-DATE-ASPIRE-BIOPHARMA-INC |
62%
|
ing United States ORAL MUCOSAL FORMULATIONS OF ONDANSETRON 63/970,377 28-Jan-2026 Pending United States VARDENAFIL (OMNIBUS) 63/890,248 29-Sep-2025 Pending United States CAFFEINE (OMNIBUS) 63/890,248… |
| COBRA-ALTERNATIVE-CAPITAL-STRATEGIES-LLC |
COBRA-ALTERNATIVE-CAPITAL-STRATEGIES-LLC |
62%
|
tional Debentures upon the mutual agreement of the Company and the holders of Debentures representing at least a majority of the aggregate principal and interest owed under the outstanding Debentures… |
| DELAWARE-GENERAL-CORPORATION |
DELAWARE-GENERAL-CORPORATION |
62%
|
3746 of the Puerto Rico General Corporations Act (as amended) and Section 388 of the Delaware General Corporation Law. Pursuant to the Aspire Domestication, Aspire’s jurisdiction of incorporation was… |
| DESERT-STREAM-INC |
DESERT-STREAM-INC |
62%
|
Although we rely on contract manufacturers, we have personnel with manufacturing experience to oversee our relationships with contract manufacturers. We entered into a development and manufacturing a… |
| NEW-SPONSOR-VISIOX-VKSS-CAPITAL-LLC |
NEW-SPONSOR-VISIOX-VKSS-CAPITAL-LLC |
62%
|
n Agreements (each, a “First Subscription Agreement”) with the New Sponsor, Visiox, VKSS Capital, LLC, an affiliate of, and an entity under common control with, the New Sponsor (the “Affiliate”), and… |
| POWERUP-ACQUISITION-CORP |
POWERUP-ACQUISITION-CORP |
62%
|
ing United States ORAL MUCOSAL FORMULATIONS OF ONDANSETRON 63/970,377 28-Jan-2026 Pending United States VARDENAFIL (OMNIBUS) 63/890,248 29-Sep-2025 Pending United States CAFFEINE (OMNIBUS) 63/890,248… |
| POWERUP-MERGER-SUB-II-INC |
POWERUP-MERGER-SUB-II-INC |
62%
|
ing United States ORAL MUCOSAL FORMULATIONS OF ONDANSETRON 63/970,377 28-Jan-2026 Pending United States VARDENAFIL (OMNIBUS) 63/890,248 29-Sep-2025 Pending United States CAFFEINE (OMNIBUS) 63/890,248… |
| REVERSE-RECAPITALIZATION-ASPIRE-BIOPHARMA-INC |
REVERSE-RECAPITALIZATION-ASPIRE-BIOPHARMA-INC |
62%
|
ing United States ORAL MUCOSAL FORMULATIONS OF ONDANSETRON 63/970,377 28-Jan-2026 Pending United States VARDENAFIL (OMNIBUS) 63/890,248 29-Sep-2025 Pending United States CAFFEINE (OMNIBUS) 63/890,248… |
| REVERSE-RECAPITALIZATION-POWERUP-ACQUISITION-COR |
REVERSE-RECAPITALIZATION-POWERUP-ACQUISITION-COR |
62%
|
3746 of the Puerto Rico General Corporations Act (as amended) and Section 388 of the Delaware General Corporation Law. Pursuant to the Aspire Domestication, Aspire’s jurisdiction of incorporation was… |
| SPONSOR-SRIRAMA-ASSOCIATES-LLC |
SPONSOR-SRIRAMA-ASSOCIATES-LLC |
62%
|
ription Agreements (each, a “First Subscription Agreement”) with the New Sponsor, Visiox, VKSS Capital, LLC, an affiliate of, and an entity under common control with, the New Sponsor (the “Affiliate”… |
